CryoLife Reports Second Quarter Financial Results
ATLANTA, July 28, 2015 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the second quarter and first six months of 2015.
Pat Mackin, Chairman, President and Chief Executive Officer, said, "During the quarter we continued to execute on our growth strategy with solid progress on several of our top organizational objectives. In June, we announced plans to transition to a direct sales model in France, advancing our strategic presence in international markets. Earlier this month, we received an expanded indication for BioGlue in Japan, which doubled our market opportunity and is consistent with our strategy to gain new indications for our product portfolio."
Help employers find you! Check out all the jobs and post your resume.
Pat Mackin, Chairman, President and Chief Executive Officer, said, "During the quarter we continued to execute on our growth strategy with solid progress on several of our top organizational objectives. In June, we announced plans to transition to a direct sales model in France, advancing our strategic presence in international markets. Earlier this month, we received an expanded indication for BioGlue in Japan, which doubled our market opportunity and is consistent with our strategy to gain new indications for our product portfolio."
Help employers find you! Check out all the jobs and post your resume.